Tempus AI stock gains as Cantor issues new Overweight (TEM)

Piper Sandler upgraded Tempus AI (TEM) to Overweight, raising its price target to $76 from $56. Analyst David Westenberg cited three key growth drivers for the AI-driven diagnostics company.

Piper Sandler upgraded Tempus AI (TEM) to Overweight with a $76 price target, citing the Personalis acquisition, INTerpath-001 study results, and FDA clearance of the xT CDx test. TEM shares rose 2.1-2.5% in premarket trading. Canaccord Genuity maintained a Buy rating with an $80 target.

Tempus AI Inc (TEM) shares rose 2.1% premarket after Piper Sandler upgraded it to Overweight with a $76 price target. Analyst David Westenberg cited three growth drivers, including the pending Personalis acquisition and FDA approval of tumor-only xT CDx. The previous Neutral rating was due to AI sentiment driving valuation.

Tempus AI stock rose 2.7% in pre-market trading after Piper Sandler upgraded it to Overweight with a $76 price target, citing growth catalysts. Canaccord Genuity reiterated its Buy rating and $80 target, praising the company's Personalis acquisition. Tempus AI reported Q2 profitability and raised 2026 revenue guidance to $1.6B. The move contrasts with broader market declines.

Ark Invest's ARK Innovation ETF, managed by Cathie Wood, allocated $1.4B to three AI-related stocks: Tesla (TSLA) with a $595M position and $2,600 price target by 2029, Tempus AI (TEM) with a $402M position, and SpaceX (SPCX) with a $378M position. The ETF has $6.42B in assets under management.

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical